31.7 C
Vientiane
Saturday, June 7, 2025
spot_img
Home Blog Page 21

Translators’ Voices: China shares technological achievements with the world for mutual benefit

BEIJING, June 3, 2025 /PRNewswire/ — May 30, 2025 marks the ninth National Science and Technology Workers Day. In the early morning of the previous day, Tianwen-2, the country’s first asteroid probe and sampling mission, soared into the sky, carrying with it humanity’s aspirations for the stars and the universe.

The nation will thrive when science and technology develops, and the country will be strong when science and technology becomes advanced. The book series of Xi Jinping: The Governance of China contains multiple important speeches on science and technology. In the article “Strive for Greater Strength and Self-Reliance in Science and Technology” included in the fourth volume of the book series, President Xi emphasized that science and technology respond to the call of the times and have a global impact; they belong to all of humanity. “We should participate to the full in global science and technology governance, contribute Chinese wisdom, and shape a philosophy of technology for good purposes, so that science and technology better serve human wellbeing, and enable China’s science and technology industry to contribute more to building a global community of shared future!”

In the fifth installment of the “Decoding the Book of Xi Jinping: The Governance of China” series, the Global Times focuses on the theme of “practicing the philosophy of technology for good purposes and polishing China’s new name card in scientific and technological innovation.” We continue to invite Chinese and international scholars, translators of the work, practitioners of its concepts, and overseas readers to share their insights, understandings and reflection on China’s philosophy of science and technology development and international cooperation.

In the fifth article of the “Translator’s Voices” column, Global Times (GT) reporter Ma Ruiqian talked to Tomokazu Ueno (Ueno), a Japanese expert at the Center for Asia-Pacific of China International Communications Group. Ueno was involved in the translation and editorial work for the Japanese editions of Xi Jinping: The Governance of China.

GT: China’s scientific and technological development over the past decades – especially in recent years – has drawn global attention. Some say that technological innovation has become a “new calling card” of China. Do you agree with this view? You’ve mentioned that the application of technology in everyday life has brought greater convenience to ordinary people. What experiences from your work and life in China have led you to feel this way?

Ueno: I fully agree with this view – technology has indeed become one of the symbols of China’s modernization. What impresses me most is how quickly technological applications are integrated into society and made practical. For example, when I first arrived in Beijing and rented an apartment through a real estate agency, I was amazed to find that the entire rental process could be completed through a smartphone app. At places like train stations and hospitals, online systems are also widely used, so there’s almost no need to wait in long lines like before.

What also shocked me was that not only young people, but even most elderly people can use smartphones proficiently. Nearly all purchases can be made via mobile payment, which brings great convenience to daily life. To be honest, after getting used to this lifestyle, every time I go back to Japan to visit family, I find it a bit troublesome to carry cash, a wallet, transportation cards and various point cards again.

GT: Yes, technological innovation not only facilitates the daily lives of ordinary people in China but also serves as a key driver for the high-quality development of related industries. In May, during an inspection tour in Central China’s Henan Province, President Xi, emphasized the importance of “technological empowerment” and “independent innovation.” You have witnessed firsthand how technology is empowering the logistics and agricultural sectors in Xinjiang. How do you view the significance of technological empowerment for the development of Chinese industries?

Ueno: When I was interviewing in the Xinjiang Uygur Autonomous Region, I was deeply impressed by the high level of mechanization in local agriculture. Not only are large tractors used during the harvest, but new agricultural technologies are also widely applied in planting methods, field management, product transportation, environmental protection and water conservation. Agricultural technology is widely applied across the board. I realized that in China, even agriculture – one of the most traditional industries – is actively embracing high-tech tools. This not only significantly increases farmers’ incomes but also strongly boosts local development.

This example shows that China clearly understands that in order to improve people’s livelihoods and help them lead better lives, it is essential to revitalize local industries and promote sustainable development in different regions. The key to achieving this is technological innovation. In China, progress in high technology is closely tied to improvements in living standards.

GT: The fourth volume of Xi Jinping: The Governance of China includes an article titled “Strive for Greater Strength and Self-Reliance in Science and Technology.” In the article, President Xi points out that “science and technology respond to the call of the times and have a global impact; they belong to all of humanity.” How do you understand the “global impact” of science and technology as mentioned by President Xi?

Ueno: The way I understand this is that science and technology know no borders – they can bring benefits to the entire world and help address global challenges. China has consistently emphasized contributing to the world through “Chinese wisdom” and “Chinese solutions,” and it has put this philosophy into practice. Chinese technologies and their applications have already played a role in many areas around the world – including environmental protection, poverty alleviation, industrial development and improvements in people’s livelihoods – achieving notable results.

There is no doubt that the path China is taking – one that respects the idea that science and technology respond to the call of the times and have a global impact – is the right path for today’s world.

GT: At the meeting with China’s sci-tech workers in 2024, President Xi said that Chinese modernization should be supported by sci-tech modernization. You will soon host the fifth season of Finding Answers in China, which also focuses on Chinese modernization. How do you understand the idea that science and technology “respond to the call of the times”? How do you think sci-tech modernization has contributed to the success of Chinese modernization?

Ueno: I believe that “responding to the call of the times” means that science and technology reflect the defining features of a given era and serve as a driving force that propels modern society forward.

One of my strongest impressions regarding this idea came during an interview I conducted for Finding Answers in China, when I spoke with a Japanese entrepreneur engaged in water treatment projects in China. He remarked that while some countries still only prioritize development at the expense of environmental protection – and some leaders even continue to question the reality of global warming – China, along with the global mainstream, has shifted toward emphasizing environmental.

Environmental protection technology is one of the most representative fields that respond to the call of the times, and I’ve personally witnessed how China has significantly increased its attention and investment in this area over the past decade. This perfectly embodies the principle of “green development” emphasized in Chinese modernization – using technology to resolve the tension between development and the environment, and striving for harmonious coexistence between humanity and nature.

GT: In his article “Strive for Greater Strength and Self-Reliance in Science and Technology,” President Xi stated, “We should participate to the full in global science and technology governance, contribute Chinese wisdom, and shape a philosophy of technology for good purposes.” In your view, what is the significance of China’s philosophy and practice of “technology for good purposes” for the international community, especially for the vast number of Global South countries?

Ueno: Science and technology have a dual nature – depending on how they are used, they can either advance human development or cause harm. The philosophy of “technology for good purposes” is essentially a profound proposition about how a country should make good use of its scientific and technological resources within the international community.

From a global perspective, developing countries with relatively weak scientific foundations have an even greater need for science and technology to achieve development. China not only makes active calls, but also takes concrete actions to share its technological achievements with these countries, aiming to bring benefits to all of humanity. This approach emphasizes not monopoly over technology and wealth, but sharing and mutual benefit. Such a philosophy helps narrow the development gap between nations and thereby promotes global stability and prosperity.

GT: What are your expectations for China’s further participation in global science and technology governance and its growing role in the future of technological development? In Japan, there are sometimes mixed views regarding China’s pursuit of self-reliance and its technological rise. What is your opinion on this? And what message would you like to share about bilateral cooperation in the field of science and technology?

Ueno: In interviews with Japanese companies operating in China, I’ve noticed that many of them are now not only setting up manufacturing bases in China but also relocating their research and development centers here. I believe there is already a solid foundation and a wealth of achievements in ChinaJapan cooperation in science and technology, with considerable potential for further growth. Looking ahead, I hope both sides can continue to expand collaboration based on their respective strengths.

However, especially since the beginning of this year, there seems to be a growing headwind against cooperation. Science, by its nature, is a pursuit of rationality. It is regrettable when irrational political interference obstructs scientific collaboration. China has not compromised under such pressure and continues to uphold the principle of win-win cooperation. I can sense that China is playing an increasingly important role in guiding the world toward the right path.

welzo Establishes New Subsidiary in Singapore to Accelerate Expansion into Southeast Asia

FUKUOKA, Japan, June 3, 2025 /PRNewswire/ — welzo Inc., an innovation-driven company in the agri-horticultural sector (Head Office: Hakata-ku, Fukuoka City, Fukuoka Prefecture; President and CEO: Yoshifumi Kanao), has established a wholly owned subsidiary, welzo Singapore PTE. LTD., in Singapore as of June 2, 2025. This move marks a significant step in accelerating its  expansion into the Southeast Asian market and strengthening its global business development.

Background and Purpose

welzo has been actively expanding its business both domestically and internationally. Considering the rapid growth and diverse opportunities in the Southeast Asian market, weve strategically chosen Singapore as its regional base. With its excellent business environment and international connectivity, Singapore serves as a key hub for accessing ASEAN countries.

Business Activities of the New Office

Its Singapore office will serve as a central hub for marketing and business development across Southeast Asia, focusing on the following key areas:

– Development and Execution of Marketing Strategies for Southeast Asia
  welzo will implement promotional initiatives tailored to the market characteristics and consumer trends of each country, aiming to enhance brand recognition and expand sales channels. The company will also actively participate in trade shows and collaborate with local partners on marketing efforts.

– Import and Export of Agricultural Products, Feed Ingredients, and Pet Supplies
  through partnerships with local agricultural and pet-related businesses, we will establish a responsive supply system.  The company will promote the export of high-quality, safe Japanese products and the import of raw materials that meet local needs.

– Building Local Partnerships and Optimizing the Supply Chain
  Its Singapore office will centrally manage logistics, customs, and quality control operations to establish a more efficient and flexible supply chain.

– Recruitment and Development of Local Talent
  we will actively recruit skilled local professionals to promote regionally rooted business operations.  The company aim to provide multilingual and culturally sensitive services.

This new office will serve as a core base for its Southeast Asian operations and is expected to play a pivotal role in future regional expansion and global business growth. By leveraging its  Singapore office, we will strengthen its  ability to deliver value tailored to local needs and foster co-creation with local communities.

The welzo Group remains committed to contributing to a sustainable global society by promoting environmentally and socially responsible business practices. Through collaboration and co-creation with diverse partners across regions and industries, we aim to deliver new value on a global scale.

Yoshifumi Kanao, President & CEO of welzo Inc.
Yoshifumi Kanao, President & CEO of welzo Inc.

Comment from Yoshifumi Kanao, President & CEO of welzo Inc.

“Singapore is not just a gateway to Southeast Asia—it’s a global hub where innovation and agriculture can converge. With this new subsidiary, we aim to deliver high-quality Japanese products to local markets while building sustainable partnerships rooted in mutual growth. This marks a crucial step in our journey toward global co-creation.”

Overview of the New Subsidiary

Company Name: welzo Singapore PTE. LTD.
Address: 80 Robinson Road #10-01A Singapore 068898
Date of Establishment: June 2, 2025
Main Business Activities: marketing in Southeast Asia; import/export of agricultural products, feed ingredients, and pet supplies

Company Overview: welzo Inc.

welzo Inc. is a specialized trading company that provides products and services to enrich lives and promote a sustainable society through food and agriculture. Formerly known as Nichiryu Nagase, the company celebrated its  101st anniversary in 2022 and changed the company name to welzo Inc. on January 1, 2023. With 24 offices across Japan, welzo primarily operates in the B2B sector, handling agricultural materials, home gardening supplies, and feed ingredients. The company actively collaborate with internal and external partners and leverages IT and AI technologies to address pressing societal challenges in Japan.

Head Office: 1-14-3 Hakata Ekihigashi, Hakata-ku, Fukuoka City, Fukuoka Prefecture
President and CEO: Yoshifumi Kanao
Established: August 1952 (Founded August 1921)
Capital: 470 million yen
Sales: 50.137 billion yen (FY ending December 2024)
Business: Specialized trading company handling agricultural materials, home gardening supplies, and feed ingredients

2025 ASCO Presentation: Innovent Biologics Announces Updated Data of IBI354 (Novel anti-HER2 ADC) From the Phase 1/2 Clinical Study in Advanced Ovarian Cancer, Breast Cancer and Other Solid Tumors

SAN FRANCISCO and SUZHOU, China, June 3, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, updated the clinical data of IBI354 (HER2 monoclonal antibody-camptothecin derivative conjugate) in advanced solid tumors at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

IBI354 has demonstrated promising anti-tumor efficacy and favorable safety profiles across multiple solid tumors. It not only holds potential to deliver a new generation of ADC therapies characterized by “high potency and low-toxicity” for tumor types such as ovarian cancer and breast cancer, but also validates the advantages of Innovent’s ADC technology platform. The results of IBI354 lays the foundation for the subsequent development of Innovent’s next-generation of bispecific ADCs and dual-payload ADCs, marking a milestone in Innovent’s next-generation “IO+ADC” oncology development strategy.

The data presented is from a Phase 1/2 clinical study (NCT05636215) aimed at evaluating the safety, tolerability, and preliminary efficacy of IBI354 in participants with advanced solid tumors. As of March 24, 2025, a total of 368 participants with advanced solid tumors were enrolled and received different doses of IBI354 monotherapy, the median follow-up duration was 11.5 months (range: 0.7-19.6), the median treatment duration was 27.0 weeks (range: 3.1-81.3) and 74 (20.1%) pts were still on treatment. The tumor types including 178 with breast cancer, 92 with ovarian cancer, 38 with colorectal cancer, and 60 with other tumors.

IBI354 monotherapy demonstrated excellent safety profile

  • The dosage was escalated to 18mg/kg, with no DLT events observed.
  • The most common treatment-related adverse events (TRAEs) were anemia, nausea, and white blood cell count decreased. The incidence of interstitial lung disease (ILD) was only 1.9%, all were grade 1-2.
  • Overall, 27.4% of patients experienced TRAEs ≥ grade 3, 17.7% experienced TRAEs leading to dose interruption, 2.7% experienced TRAEs leading to dose reduction and 1.6% experienced TRAEs leading to discontinuation, with no TRAEs leading to death.

IBI354 monotherapy showed promising efficacy signals in multiple tumor types

  • In HER2-positive breast cancer cohort (n= 88, treated at 6~15mg/kg, the median prior treatment lines was 4), the confirmed objective response rate (ORR) and the disease control rate (DCR) were 59.1% and 90.9%, respectively. In 9 mg/kg Q3W subgroup (n=29), the ORR and the DCR were 72.4% and 89.7%, respectively. The median progression-free survival (PFS) was 14.1 months (95% CI: 8.3-not calculable [NC]) with events of 48.3%. The median overall survival (OS) was immature with events of 3.4%.
  • In ovarian cancer cohort (n=92, treated at 2~12mg/kg, the median prior treatment lines was 3), the cORR was 41.2% and the DCR was 82.0%. In the 12mg/kg Q3W subgroup (n=40), the cORR reached 55.0% and the DCR was 90.0%. In participants with HER2 1+ (n=27), the ORR reached 55.6% and the DCR was 88.9%. As of the data cutoff date, the median follow-up time was 11.9 months, and the median PFS was 7.1 months (95% CI: 5.2−10.8) in 12mg/kg Q3W dose group. The median OS was not mature with events in 14 (34.1%) pts and a 12-month OS rate of 63.9% (95% CI: 45.0−77.8).

Professor Qi Zhou, Chief Physician at the Gynecologic Oncology Center of Chongqing University Affiliated Cancer Hospital and the Principal Investigator of the gynecologic oncology cohort study, stated, “The treatment of platinum-resistant recurrent ovarian cancer is difficult and the prognosis is poor, threatening the life and health of women. Extending PFS and OS in platinum-resistant recurrent ovarian cancer patients remains a clinical challenge for gynecological oncologists. ADC drugs provide a new direction for overcoming resistance mechanisms by precisely delivering cytotoxic agents. HER2, as a validated solid tumor target, has made breakthroughs in breast and gastric cancer fields, while the novel ADC drug IBI354 shows broad-spectrum antitumor activity through unique design in HER2 low-expression (IHC 1+) platinum-resistant ovarian cancer. In the Phase 1 study with a dose of 12mg/kg Q3W, IBI354 demonstrated an ORR of 55.0% and DCR of 90.0%, with a median PFS reaching 7.1 months. The safety profile was very good without common severe interstitial lung disease or ocular toxicity seen in other ADCs. These results significantly outperform traditional chemotherapy regimens, suggesting its potential breakthrough efficacy in the platinum-resistant population. The Phase 3 study of IBI354 in platinum-resistant ovarian cancer (HeriCare-Ovarian01) has been initiated, and I am looking forward to the results, as well as the further validation of the long-term benefits for patients receiving IBI354.”

Doctor Charlotte Rose Lemech from Scientia Clinical Research Ltd, Australia, stated: “Breast cancer is one of the most common malignant tumors among women globally and remains a leading cause of cancer-related deaths. The amplification or overexpression of HER2 (human epidermal growth factor receptor 2) is recognized as a key driver in the development, progression, and metastasis of breast cancer, with approximately 15%-20% of breast cancer patients exhibiting HER2 overexpression. ADCs have become the new standard treatment for later line HER2 positive breast cancer. In this Phase 1 study, IBI354 has demonstrated encouraging efficacy and safety data, achieving high ORR and DCR especially in 9 mg/kg Q3W subgroup. Long term survival was also achieved with the median PFS of 14.1 months. IBI354 also differentiates itself from other HER2 targeted therapies with its safety profile. The incidence of interstitial lung disease was extremely low and most of the hematological toxicity and gastrointestinal adverse events were mild to moderate and can be effectively managed with standard supportive care. This favorable safety profile enhances the clinical application potential of IBI354 and we look forward to IBI354 achieving more breakthroughs in the field of breast cancer treatment.”

Dr. Hui Zhou, Senior Vice President of Innovent, stated: “With the rapid development of ADC drugs in the field of tumor treatment, Innovent is steadily advancing its strategic layout in the ADC field. At this year’s ASCO conference, we update the safety and efficacy data of IBI354 across various advanced solid tumors. These clinical results not only confirm the potential therapeutic value of IBI354 but also demonstrating Innovent’s innovative strength and technological advantages in ADC drug development. The phase 3 study of IBI354 in platinum-resistant ovarian cancer has been initiated, and more clinical studies are also planned. We will continue to invest in next-generation ADC molecules, aiming to address unmet clinical needs and bring patients with more effective and safer treatment options.”

About IBI354 (Anti-HER2 Antibody-Camptothecin Derivative Conjugate)

IBI354 is an innovative HER2-targeted antibody–camptocinin derivative conjugate developed by Innovent’s proprietary SoloTx ADC platform. With a drug-to-antibody ratio (DAR) of 8, IBI354 delivers a high payload of effective drugs to tumors. The highly hydrophilic linker design contributes to its excellent biophysical and pharmacokinetic (PK) properties, while the hydrophobic payload enhances its bystander effect, targeting adjacent antigen-low or negative tumor cells. IBI354 exhibits extremely low exposure of free toxin in circulation and has an ideal safety profile based on pre-clinical and clinical studies. IBI354 has demonstrated remarkable anti-tumor activity in various tumor-bearing mice models, particularly in those resistant to HER2-targeted therapies and in metastatic tumors. Innovent Biologics is conducting clinical studies to assess the efficacy and safety of IBI354 for multiple advanced solid tumors.

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 15 products in the market. It has 3 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center.

Guided by the motto, “Start with Integrity, Succeed through Action,” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement:

1Innovent does not recommend the use of any unapproved drug (s)/indication (s).

2Ramucirumab (Cyramza®) and Selpercatinib (Retsevmo®) and Pirtobrutinib (Jaypirca®) were developed by Eli Lilly and Company.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent’s competitive environment and political, economic, legal and social conditions.

Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.

Jenscare released 30-day follow-up results of LuX-Valve Plus TRINITY study and 1-year follow-up results of JensClip TMVr at EuroPCR 2025

BEIJING, June 3, 2025 /PRNewswire/ — Jenscare Scientific Co., Ltd. (“Jenscare” or the “Company”) (HKEX: 9877), an innovative medical device company, recently released 30-day follow-up results of TRINITY Trial of LuX-Valve Plus, a promising self-developed TTVR system, and 1-year outcomes of JensClip, a proprietary TMVr system, at EuroPCR 2025 in Paris, France.

30-Day Follow-up Results of LuX-Valve Plus TRINITY Study

TRINITY is a global prospective, multicenter, single-arm clinical trial, which primarily aims to evaluate the safety and efficacy of LuX-Valve Plus in application on patients with severe tricuspid regurgitation and high surgical risk. The study enrolled 161 patients from 20 centers around the world, among which, 18 centers were from France, Germany, Spain, Denmark, and the UK.

The average age of the patients is about 77 years old with an average STS score of 9.92% (14.45% of Roll-in group). For FAS group, 72.48% of the patients has atrial fibrillation, 32.20% has left heart surgery/intervention, 26.85% has pacemaker/ICD implanted. For Roll-in group, 91.76% of the patients has atrial fibrillation, 41.67% has left heart surgery/intervention, 25.00% has pacemaker/ICD implanted. Patients are combined with multi other comorbidities, which formed a poor baseline and increased the risks of surgical treatment or difficulties of other interventional therapies. Over 75% of enrollments utilized valve sizes between 55mm and 70mm. The results show that the device success rate is about 97%, and the average device operation time is around 41.60 minutes with the shortest time being 11 minutes.

The safety indicators show that the overall CEC-adjudicated composite events rate at 30-day is 14.8% of FAS group and 14.9% with Roll-in group included. For FAS group, cardiovascular mortality is 1.3%, the incidence of strokes and non-selective tricuspid/valve surgery/intervention post procedure are both 0.7%, major cardiac structural complications is 2.0%, severe bleeding (including fatal, life-threatening and extensive bleeding as defined by MVARC) is 4.0%, new pacemaker implantation due to AVB is only 8.7%. No events prevailed in myocardial infarction, new onset renal failure, major access site and vascular complications, and device-related pulmonary embolism. For Roll-in group, both non-selective tricuspid/valve surgery/intervention post procedure and new pacemaker implantation showed one event. And there are no events prevailed in cardiovascular mortality, myocardial infarction, strokes, new onset renal failure, severe bleeding, major cardiac structural complications, and device-related pulmonary embolism.

The efficacy indicators show that the tricuspid regurgitation (TR) grade, NYHA classification, and QoL improved significantly at 30 days. For FAS group, 95.7% of the patients show no above moderate TR. 84.1% of them show postoperative NYHA class I/II. KCCQ score increased by around 14 pts on average. For Roll-in group, 91.7% of the patients show no above moderate TR. 58.3% of them show postoperative NYHA class I/II. KCCQ score increased by around 18 pts on average.

Professor Thomas Modine concluded that LuX-Valve Plus TTVR system is an innovative device indicated for high-surgical risk patients with severe TR and demonstrates several advantages. First, it features radial-force independent anchoring mechanism, which is designed particularly for TV. Second, it indicates low demands on imaging quality, which is expected to significantly reduce device time. Third, it provides large size options, which enables wide applicability on large TV anatomies. The 30-day clinical outcomes of TRINITY trial demonstrate good safety and performances, with improvements in quality of life and low rate of composite adverse events. The wide application on large anatomy patients provides encouraging treatment options for severe TR patients, while current therapies are limited. Further follow-ups of TRINITY trial and the U.S. FDA clinical study on LuX-Valve Plus are underway.

One-Year Follow-Up Results of JensClip

The study of JensClip TMVr system is a prospective, multicenter, single-arm clinical trial, which primarily aims to evaluate the safety and efficacy of JensClip in application on patients with symptomatic degenerative mitral regurgitation (DMR) at high surgical risk. The study enrolled 114 patients from 18 centers in China with an average age of 71 years old.

The average age of the patients is about 71 years old with an average STS score of 7.65. 63.2% of the patients has hypertension history, 41.2% has coronary artery disease, 30.7% has atrial fibrillation, and 91.2% has pre-operative NYHA class III/IV. The results show that the device success rate at 30 days is about 97%, and the average device operation time is around 67.53 minutes.

The safety indicators show that all-cause mortality is 1.8%. The incidence of unplanned mitral valve intervention/surgery is 5.3%, and that of stroke is 1.8%. The incidence of renal failure, myocardium infarction, major bleeding, device releasing/locking failure, and clip related hemolysis are all 0.9%. No events prevailed in SLDA and device related air embolism.

The efficacy indicators show that the mitral regurgitation (MR) grade, NYHA classification, and QoL improved continuously at 1 year. 96.29% of the patients show no above moderate MR. 93.46% of them show postoperative NYHA class I/II. KCCQ score increased by around 20 pts on average. 6MWD increased by around 82m from the baseline.

Professor Xiangbin PAN concluded that JensClip is an innovative device intended for severe DMR, providing easy and reliable operation. The 1-year clinical outcomes demonstrated procedural safety and durable MR reduction.

About LuX-Valve Plus

LuX-Valve Plus, the proprietary TTVR system, is designed for patients with severe tricuspid TR and high surgical risk. LuX-Valve Plus breaks through multiple technical difficulties in tricuspid valve interventional therapy. With the design of innovative “interventricular septum anchoring” and “leakproof self-adaptive braided ring”, which enables non-radial anchoring of the valve implant and tend to effectively prevent AV Block. LuX-Valve series product is designated by the FDA as a breakthrough device, is enrolled in the Total Product Life Cycle Advisory Program (TAP) pilot of the FDA and is selected for the Expert Panel Scientific Advice Pilot by the EMA. As of the latest update, over 700 implantation cases have been completed worldwide with the LuX-Valve series products, and the longest follow-up record has been over 6 years.

About JensClip

JensClip, the proprietary TMVr system, features an innovative self-locking design, which is expected to effectively improve mitral regurgitation and reduce leaflet tension. The valve clip allows for flexible shape adjustments, which is expected to enhance procedural safety and improve intraoperative maneuverability. Furthermore, its one-piece release mechanism is designed to minimize potential mis-operation risks associated with staged detachment, effectively reducing device operation time.

About Jenscare

Jenscare is an innovative medical device company, established in 2011. The Company has achieved a complete product layout of interventional treatment solutions for different types of structural heart diseases, including tricuspid valve disease, mitral valve disease, aortic valve disease and so on. LuX-Valve series products, the core products, are innovative in the design concepts and treatment solutions for complex tricuspid anatomies. It is expected to become one of the first commercialized tricuspid valve replacement products in the world.

2025 ASCO |Oral Presentation: Disitamab Vedotin Achieves Stellar Efficacy as First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Gastric Cancer

YANTAI, China, June 3, 2025 /PRNewswire/ — On June 2 (Chicago time), in an oral presentation at the 2025 ASCO Annual Meeting, Dr. Lin Shen from Beijing Cancer Hospital presented the results of a Phase 2 clinical study conducted in China evaluating the efficacy and safety of disitamab vedotin (DV), developed by Remegen Co., Ltd., and toripalimab (PD-1) combined with CAPOX or trastuzumab as the first-line therapy for HER2-expressing patients with locally advanced or metastatic (la/m) gastric cancer. Comparing to the control group who received standard-of-care therapy, the DV combination therapy demonstrated clinically meaningful efficacy improvement, potentially to benefit patients who are non-responders to traditional targeted therapies.

The data presented are from the Phase 2 part of a randomized, multi-cohort, seamlessly connecting Phase 2/3 study, which enrolled systematic chemotherapy-native patients with different HER2 expression levels. As of April 7, 2025, the results showed:

  • Among HER2-overexpressing gastric cancer patients, compared to the PD-1-trastuzumab-CAPOX combination therapy, DV and PD-1 + chemotherapy as well as DV and PD-1 + trastuzumab both demonstrated statistically significant efficacy and favorable safety profiles.
    • Objective response rate (ORR): 66.7% vs 82.4% vs 68.8%;
    • Median progression-free survival (mPFS): NR vs NR vs 14.1 months, with risk of disease progression decreasing by 54%(HR=0.46)and 41% (HR: 0.59);
    • 12-month PFS rate: 66.3%, 67% and 53.6%;
    • Common TRAEs of grade 3-5: diarrhea, neutrophil count decreased, platelet count decreased, etc.
  • In patients with HER2-low-expressing gastric cancer, promising efficacy was observed with DV + PD-1 + CAPOX comparing to PD-1 + CAPOX, with a manageable safety profile.
    • ORR: 72.0% vs 47.8%;
    • mPFS: 9.9 vs 7.2 months, with risk of disease progression decreasing by 31% (HR: 0.69);
    • Common TRAEs of grade 3-5: diarrhea, neutrophil count decreased, platelet count decreased, etc.
  • Dose optimization conducted in patients with HER2-median/low-expressing gastric cancer. Compared to PD-1 + CAPOX, DV at 2.5 mg/kg or 2.0 mg/kg combined with PD-1 + reduced-dose CAPOX showed significant efficacy, and better safety over the full-dose chemotherapy.
    • ORR: 71.4% vs 66.7% vs 56.3%;
    • 6-month PFS rate: 71.4%,72.7% and 53.3%.

Globally, this is the first study to explore the triple combination therapy of “HER2 ADC + PD-1 + targeted medication” as first-line treatment of patients with la/m gastric cancer, pioneering a new mode of synergistic therapy. The multi-cohort design of this study provides precision treatment regimen for gastric cancer patients with different level of HER2 expression. For the HER2-overexpressing gastric cancer patients, DV + PD-1 + trastuzumab has the potential to become the new standard first-line treatment; for the HER2-low-expressing gastric cancer patients, DV + PD-1 + chemotherapy has the potential to fill the treatment gap of these patients. Based on the data obtained from the phase 2 study, the phase 3 clinical study of the triple combination therapy in patients with HER2-median/low-expressing gastric cancer has been initiated in April, 2025, in which 616 participants were planned to be enrolled, to further validate the efficacy of the DV combination therapy.

Gastric cancer is the fifth most common malignant tumor in the world, and China accounts for about 42.6% of new cases and 45.0% of deaths worldwide. HER2 is an important target in the treatment of gastric cancer, while the traditional targeted drug trastuzumab is only effective in the population with high expression (IHC 3+ or IHC 2+/FISH+), and can easily become resistant. There is a lack of effective targeted therapy options for patients with low/median HER2 expression (IHC 1+ or IHC 2+/FISH-), and the efficacy of chemotherapy combined with immunotherapy is not satisfactory.

As the first domestic HER2-targeted ADC drug in China, DV not only precisely kills tumor cells with HER2 over expression but also attacks adjacent cells with HER2 low expression through the bystander effect. Preclinical studies have also shown that the combination of DV with PD-1 inhibitor and trastuzumab can enhance anti-tumor activity.

ASCO 2025 Oral Presentation: Innovent Biologics Announces Updated Data of IBI343 (Novel Anti-CLDN18.2 ADC) From the Phase 1 Clinical Study in Patients with Advanced Pancreatic Cancer

SAN FRANCISCO and SUZHOU, China, June 3, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, updated the Phase 1 study results of IBI343, a novel anti-CLDN18.2 ADC, for the treatment of advanced pancreatic cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

With extended follow-up and more mature data on progression-free survival (PFS) and overall survival (OS), IBI343 has demonstrated promising therapeutic efficacy in patients with CLDN18.2-positive advanced pancreatic cancer. These encouraging results suggest the potential of IBI343 in this challenging-to-treat malignancy. Supported by these robust clinical findings, IBI343 has been granted Breakthrough Therapy Designation (BTD) by China’s National Medical Products Administration (NMPA). Concurrently, the Phase 1 clinical trial of IBI343 is also being conducted in the United States, where the drug candidate has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA).

Pancreatic cancer is one of the most aggressive malignancies worldwide. Most patients are diagnosed in the middle and late stages and often develop resistance to standard chemotherapy, resulting in a 5-year survival rate of less than 10%1. According to the GLOBOCAN 2022 statistics2, there are approximately 510,000 new cases and 467,000 deaths globally from pancreatic cancer each year, with China accounting for 120,000 new cases and 110,000 deaths annually.

This Phase 1/1b study is a multi-regional, dose escalation and expansion clinical trial (NCT05458219). Preliminary data were presented at ASCO 2025 and ESMO Asia 2024 and the updated results from the study’s dose-expansion cohort were presented at the 2025 ASCO as follows:

  • As of March 14, 2025, a total of 83 patients with pancreatic cancer had received at least one dose of IBI343 with a median follow-up time of 11.1 months.
  • As the data cutoff date, in patients with CLDN18.2 1+2+3+≥60% expression treated at the 6mg/kg dose (N=44), the confirmed overall objective response rate (cORR) was 22.7% and the disease control rate (DCR) was 81.8%. The median progression-free survival (mPFS) was 5.4 months, and the median overall survival (mOS) was 9.1 months. Among them, 17 patients had received only one line of prior treatment, achieving a mPFS of 5.4 months and a mOS of 12.1 months; and 18 patients had received two lines of prior treatment, the mPFS was 5.3 months and the mOS was 9.1 months.
  • The updated safety results demonstrated the favorable safety profile of IBI343 with a consistently low rate of gastrointestinal toxicity and no new safety signals. 98.8% of the patients experienced treatment-emergent adverse events (TEAEs), with the most common TEAEs being anemia, neutrophil count decreased, and white blood cell count decreased. Notably, no ≥ grade 3 nausea and vomiting occurred.

Professor Xianjun Yu from Fudan University Cancer Hospital, said, “Pancreatic cancer is one of the most malignant tumors of the digestive tract. Most patients are already in the advanced stage when diagnosed, and the 5-year survival rate is only about 10%1. Currently, chemotherapy is still the main first- and second-line treatment for advanced pancreatic cancer. The clinical options for second-line treatment are particularly limited, with a chemotherapy response rate of only 6-16%, median progression free survival of 2 to 5 months, and a median survival of approximately 6 to 9 months3, representing an urgent clinical need. With longer follow-up, the mature PFS and OS data from the latest IBI343 update demonstrate promising therapeutic potential, suggesting a breakthrough in this difficult-to-treat malignancy.”

Dr. Hui Zhou, Senior Vice President of Innovent, said, “We are pleased to present an oral update on IBI343’s clinical data at this year’s ASCO conference. With the unique Fc-silent antibody design, stable linker and potent TOPO1i payload, IBI343 is the first ADC candidate to show encouraging efficacy and a favorable safety profile in the treatment of advanced pancreatic cancer. We hope to continue advancing the clinical trials of IBI343 for pancreatic cancer patients. Innovent will leverage its unique strengths in R&D innovation and clinical translation to develop a new generation of globally competitive oncology – focused innovative pipeline to benefit patients worldwide..”

About IBI343Anti-CLDN18.2 ADC

IBI343 is a recombinant human anti-CLDN18.2 monoclonal antibody-drug conjugate (ADC) developed by Innovent Biologics. IBI343 binds to the CLDN18.2-expressing tumor cells, the CLDN18.2 dependent ADC internalization will occur and the drug is released resulting in DNA damage and eventually apoptosis of the tumor cells. The freed drug can also diffuse across the plasma membrane to reach and kill the neighboring cells, resulting in “bystander killing effect”.

As an innovative TOPO1i ADC, IBI343 has demonstrated tolerable safety and encouraging efficacy signals in Phase 1 clinical studies. The therapeutic potential of IBI343 is currently being explored in tumor types such as gastric and pancreatic cancer.

The Phase 3 trial of IBI343 for advanced gastric / gastroesophageal junction adenocarcinoma is now recruiting patients. The relevant indication has been included in China’s NMPA breakthrough therapy list.

IBI343’s Phase 1 trial for advanced pancreatic ductal adenocarcinoma is enrolling patients in an multi-regional study. This indication has received Fast Track designation from the FDA and been included in the NMPA’s BTD list.

About Innovent Biologics

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 15 products in the market. It has 3 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.

Guided by the motto, “Start with Integrity, Succeed through Action,” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement:

1. Innovent Biologics does not recommend the use of unapproved drugs/indications.

2. Ramucirumab injection (Ciranza®), selpercatinib capsules (Ritu®) and pirtobrutinib tablets (Capra®) were developed by Eli Lilly and Company

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent Biologics, Inc. (“Innovent” or “Company”), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company’s competitive environment and political, economic, legal and social conditions.

The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.

References

1 Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7-33. doi: 10.3322/caac.21708.

2 Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 May-Jun;74(3):229-263.

3 Jemal A, Bray F, Center MM, et al. Global cancer stastics. CA Cancer J Clin, 2011, 61(2): 69-90.

 

XellSmart Secures FDA Clearance for Three Phase I INDs of Allogeneic iPSC-Derived Cell Therapies Targeting Major CNS Diseases: Parkinson’s Diseases, Spinal Cord Injury and ALS

SUZHOU, China, June 3, 2025 /PRNewswire/ — XellSmart Biomedical Co., Ltd. (Suzhou/Shanghai, China) is a leading biotechnology company dedicated to the development of innovative iPSC-derived cell therapies. To date, the company has received seven Investigational New Drug (IND) approvals for registered clinical trials from both the National Medical Products Administration (NMPA) of China and the U.S. Food and Drug Administration (FDA). All approvals focus on clinical-grade, off-the-shelf and allogeneic iPSC-derived cell therapy candidates targeting central nervous system (CNS) diseases with significant unmet medical needs, including:

Parkinsons Disease (PD), the worlds second most prevalent neurodegenerative disease affecting over 10 million patients globally (Phase I clinical trials in both China and the U.S.);

Spinal Cord Injury (SCI), a major CNS disease impacting more than 10 million patients globally (First-in-Class; Phase I clinical trials in China and the U.S.); and

Amyotrophic lateral sclerosis (ALS), a devastating rare neurodegenerative disease (First-in-Class; Phase I/II clinical trial in China and Phase I in the U.S.; designated as an Orphan Drug by the U.S. FDA).

XellSmart has completed multiple cases of iPSC-derived dopaminergic neural progenitor cell therapy for patients with Parkinson’s disease, including”the first case”in China. This clinical study was approved by the National Health Commission (NHC) of China. In the clinical study, clinical-grade iPSC-derived dopaminergic neural progenitor cells were transplanted into the putamen of the striatum in patients with moderate to advanced Parkinson’s disease. With follow-up periods exceeding 12 months, no cell therapy-related adverse events have been observed. Multiple patients showed significant improvements in key efficacy indicators, including”on/off”time duration and MDS-UPDRS scores, as well as notable enhancements in non-motor symptoms.

XellSmart is committed to developing clinical-grade, off-the-shelf allogeneic iPSC-derived cell therapies targeting central nervous system (CNS) diseases with no effective treatment options. XellSmart is at the forefront of advancing innovative iPSC-based therapies to address major and intractable CNS disorders:
In 2023, China’s first iPSC-derived cell therapy (XS228 injection), developed by XellSmart, was granted by FDA as Orphan Drug Designation (ODD) for the treatment of amyotrophic lateral sclerosis (ALS).

In 2024China’s first national-level registered clinical study of an iPSC-derived cell therapy for Parkinson’s disease—also developed by XellSmart—was approved and initiated, including the first case treated in China.

In 2024, the world’s first national-level registered clinical study of a subtype-specific iPSC-derived neural progenitor cell therapy (XS228 injection) for ALS was approved. Multiple patients, including the world’s first ALS case treated with this approach, received therapy with good safety profiles and preliminary data showing slowed disease progression.

In 2025, China’s first registrational Phase I clinical trial of an off-the-shelf allogeneic iPSC-derived dopaminergic neural progenitor cell therapy (XS411 injection) for Parkinson’s disease was launched, led by the National Neurological Disease Medical Center at Beijing Tiantan Hospital.

In 2025, China’s first randomized, double-blind, controlled Phase I/II clinical trial of XS411 injection was initiated to treat early-onset Parkinson’s disease (EOPD), led by Huashan Hospital of Fudan University, a National Neurological Disease Medical Center.

In 2025, the world’s first registrational Phase I clinical trial of an off-the-shelf, allogeneic iPSC-derived subtype-specific neural progenitor cell therapy was launched by The Third Affiliated Hospital of Sun Yat-sen University, targeting spinal cord injury (SCI) — a major neurological disorder with no effective treatment.

In 2025, the world’s first Phase I/II registrational clinical trial of XS228 injection—an off-the-shelf, allogeneic iPSC-derived subtype-specific neural progenitor cell therapy—was initiated by Peking University Third Hospital, targeting ALS, a devastating rare neurodegenerative disease.

XellSmart has established a fully dedicated, internationally competitive “All-In” team focusing on development of clinical-grade, allogeneic, off-the-shelf iPSC-derived cell therapies for central nervous system (CNS) diseases that currently lack effective treatment options. XellSmart has built a portfolio of proprietary, globally leading industrial technologies and platforms, fueling sustained in-house innovation centered on its core business. To develop iPSC-derived cell therapy candidates, XellSmart has established and operates an R&D center, a B+ and A-grade GMP manufacturing facility, and a quality control center spanning over 5,000 square meters.

Multiple clinical-grade iPSC-derived cell therapy candidates developed by XellSmart have completed core CMC development, with fully integrated clinical-grade manufacturing processes and quality control systems in place. XellSmart has successfully produced clinical batches of multiple GMP-grade iPSC-derived subtype-specific neural progenitor cell therapies, currently deployed in multiple clinical trials.

XellSmart has secured multiple rounds of financing, collectively led by renowned market-driven venture capital firms including Qiming Venture Partners, Eli Lilly Asia Ventures, Sequoia Capital China (Hongshan), and others.

Siemens Healthineers Wins Best Office Interior (Malaysia) at Asia Pacific Property Awards 2024–2025

  • New Kuala Lumpur office, designed with Space Matrix, sets a benchmark in workplace innovation and cultural expression.

KUALA LUMPUR, Malaysia, June 3, 2025 /PRNewswire/ — Siemens Healthineers Malaysia has been recognized for excellence in workplace design, winning Best Office Interior (Malaysia) at the Asia Pacific International Property Awards 2024–2025 in Bangkok. The company’s new office, designed in partnership with the global workplace design and build firm Space Matrix, reflects a thoughtful and forward-looking approach to the modern work environment.

(L–R) Nitiakaran Leo Selvaraj (Head of Marketing-Communications), Jan Tiedermann (Finance Director), and Azri Adenan (Procurement Manager) of Siemens Healthineers, with Shimin Wong (Interior Designer, Space Matrix),
(L–R) Nitiakaran Leo Selvaraj (Head of Marketing-Communications), Jan Tiedermann (Finance Director), and Azri Adenan (Procurement Manager) of Siemens Healthineers, with Shimin Wong (Interior Designer, Space Matrix),

This recognition highlights more than visual appeal. The new space brings to life the Healthineers Human-Centric Collaboration, a global approach focused on flexibility, collaboration, digital enablement, and a people-first culture. From adaptable workstations to intuitive technology and employee-centered spaces, the office is designed to support the way teams want to work today.

“This isn’t just a design recognition. It’s a reflection of how we work and what we believe in as a global healthcare company,” said Jan Tiedermann, Finance Director of Siemens Healthineers Malaysia. “The office captures who we are: innovative, people-focused, and rooted in local culture. Most importantly, it supports our purpose: We pioneer breakthroughs in healthcare. For everyone. Everywhere. Sustainably.”

Key features of the new office include open collaboration zones, flexible workstations, and Malaysia’s first Siemens Healthineers Customer Experience Center. One of the most distinctive spaces is the Work Café, often called the “social heartbeat” of the office. Designed for both casual conversations and company-wide gatherings, it modularly hosts everything from spontaneous meetups to town halls and celebrations.

Cultural storytelling played a pivotal role in shaping the design. Murals inspired by Malaysian street art, meeting rooms named after local landmarks, and other local touches give the office a strong sense of place and belonging. Every element reflects a clear commitment to the principle that form follows function, with spaces thoughtfully shaped around how Healthineers work, connect, and innovate.

“Designing the Siemens Healthineers Malaysia office was a deeply collaborative journey,” said Angela Chang, Managing Director, SEA at Space Matrix. “From the outset, our goal was to create a space that incorporates the unique blend of Siemens Healthineers’ German heritage, Malaysian culture, and healthcare innovation. This award reflects what’s possible when design is driven by purpose and shaped by the people who bring it to life.”

This award marks a key milestone for Siemens Healthineers Malaysia, recognizing its leadership in both healthcare innovation and workplace design. The new office reflects a purposeful shift in how the company works, connects, and leads. As a recipient of the International Property Awards, the space sets a new benchmark for healthcare workplaces in Malaysia and beyond.

This press release and the press picture are available here: https://www.siemens-healthineers.com/en-my/press-room/press-features/best-office-interior 

Contact for media enquiries, please get in touch with:

Siemens Healthineers
Nitiakaran (Leo) Selvaraj
Head of Marketing-Communications and Digital Engagement/Govt Affairs
+6012 393 2789 ; nitiakaran.selvaraj@siemens-healthineers.com

Space Matrix
Anjani Prakash
Global Marketing Director
+9198103-6365 ; anjani.prakash@spacematrix.com

A photo of the Work Cafe at Siemens Healthineers Headquarters
A photo of the Work Cafe at Siemens Healthineers Headquarters

A photo of the Siemens Healthineers Experience Centre in Kuala Lumpur
A photo of the Siemens Healthineers Experience Centre in Kuala Lumpur